

Question

Q29: A 50 year-old patient presents with breast cancer involving axillary and infraclavicular lymph nodes and exhibits a pCR at mastectomy and sentinel node biopsy following neoadjuvant chemotherapy. What is the current standard of care for adjuvant RT?

- A. No adjuvant RT is indicated for a pathologic complete response
- B. Adjuvant RT to the chest wall and regional nodes
- C. Adjuvant RT directed only to the undissected level 3 node
- D. Adjuvant RT directed only to the chest wall

ChatGPT-3.5

Option **B** is the current standard of care for adjuvant RT.

In patients with locally advanced breast cancer who achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy and undergo mastectomy and axillary surgery, adjuvant radiation therapy (RT) to the chest wall and regional lymph nodes is recommended, regardless of the initial clinical stage or extent of residual disease at surgery.

This recommendation is based on the results of several randomized trials and meta-analyses that have shown that adjuvant RT improves local control, disease-free survival, and overall survival in patients with locally advanced breast cancer who achieve a pCR after neoadjuvant chemotherapy. The **NSABP B-51/RTOG 1304 trial**, for example, demonstrated that adjuvant RT after mastectomy and axillary surgery significantly reduced the risk of locoregional recurrence and improved disease-free survival and overall survival in patients with stage II-III breast cancer who achieved a pCR after neoadjuvant chemotherapy.

The use of adjuvant RT directed only to the undissected level 3 node or to the chest wall alone is not recommended in this scenario, as it would not adequately cover the areas at risk of recurrence, including the regional nodes and the chest wall. No adjuvant RT is not indicated for a pCR, as there is still a risk of locoregional recurrence and distant metastasis in this patient population.

ChatGPT-4

Based on the available information, the current standard of care for adjuvant radiation therapy (RT) in this scenario is:

B. Adjuvant RT to the chest wall and regional nodes

Even though the patient has achieved a pathological complete response (pCR) after neoadjuvant chemotherapy, the involvement of axillary and infraclavicular lymph nodes at presentation is considered high-risk. Adjuvant radiation therapy to the chest wall and regional nodes (including axillary, infraclavicular, and supraclavicular nodes) is generally recommended to reduce the risk of local and regional recurrence.

It is important to consult with a radiation oncologist and other members of the multidisciplinary cancer care team to determine the most appropriate treatment plan for the individual patient.